Enterome SA的EO4010免疫疗法显示了希望,延长了晚期的结肠癌病人的寿命。 Enterome SA's immunotherapy EO4010 shows promise, extending life for advanced colorectal cancer patients.

Enterome SA报告其免疫疗法临床试验(EO4010)对某种特定类型的高级直肠癌取得了积极成果。 Enterome SA has reported positive results from a clinical trial of its immunotherapy, EO4010, for a specific type of advanced colorectal cancer. 在一项对20名病人的研究中,40%的病人在12个月后仍然活着,中位存活率为11.3个月。 In a study of 20 patients, 40% were still alive after 12 months, with a median survival of 11.3 months. 治疗显示有潜力提振免疫细胞以对抗肿瘤,表明这种癌症的患者有希望的新选择。 The treatment showed potential in boosting immune cells to fight tumors, indicating a promising new option for patients with this form of cancer.